Can Glaukos' (GKOS) Latest FDA Approval Reinforce Its Corneal Therapy Leadership? [Yahoo! Finance]
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
keratoconus, following positive results from two Phase 3 clinical trials involving more than 400 patients. This approval expands Glaukos' corneal portfolio and builds on their pioneering position, as their prior therapy Photrexa® has been the only FDA-approved corneal cross-link therapy since 2016. We'll explore how the FDA approval of Epioxa, as a new option for keratoconus, may shape Glaukos' investment narrative. The end of cancer? These 27 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. Glaukos Investment Narrative Recap To be a shareholder in Glaukos, you need confidence in the company's ability to drive innovation in ophthalmology and expand its presence in minimally invasive treatments, even as competition and reimbursement dynamics persist as core risks. The FDA approval of Epioxa adds a valuable new asset to Glaukos' corneal portfolio and may be an important short-term catalyst, thoug
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Should Glaukos' Improved Results and Raised Outlook Prompt a Closer Look From GKOS Investors? [Yahoo! Finance]Yahoo! Finance
- Glaukos Announces Participation in Upcoming Investor ConferencesBusiness Wire
GKOS
Earnings
- 10/29/25 - Beat
GKOS
Sec Filings
- 11/26/25 - Form 4
- 11/25/25 - Form 144
- 11/20/25 - Form 4
- GKOS's page on the SEC website